Adeno-associated virus gene replacement for recessive inner ear dysfunction: Progress and challenges.
Ontology highlight
ABSTRACT: Approximately 3 in 1000 children in the US under 4 years of age are affected by hearing loss. Currently, cochlear implants represent the only line of treatment for patients with severe to profound hearing loss, and there are no targeted drug or biological based therapies available. Gene replacement is a promising therapeutic approach for hereditary hearing loss, where viral vectors are used to deliver functional cDNA to "replace" defective genes in dysfunctional cells in the inner ear. Proof-of-concept studies have successfully used this approach to improve auditory function in mouse models of hereditary hearing loss, and human clinical trials are on the immediate horizon. The success of this method is ultimately determined by the underlying biology of the defective gene and design of the
SUBMITTER: Askew C
PROVIDER: S-EPMC7939749 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA